Polymorphisms in CYP1A1 and smoking: no association with breast cancer risk

Victoria M. Basham, Paul D.P. Pharoah, Catherine.S. Healey, Robert N. Luben, Nicholas E. Day, Douglas F. Easton, Bruce A.J. Ponder, Alison M. Dunning
2001 Carcinogenesis  
Several studies have investigated polymorphisms in CYP1A1 and breast cancer risk with inconsistent results. We have carried out a population based case-control study of the Thr461Asn and Ile462Val polymorphisms in CYP1A1 to clarify their importance in determining breast cancer susceptibility. A total of 1873 cases and 712 controls were genotyped for Thr461Asn and 1948 cases and 1355 controls were genotyped for Ile462Val. We have also investigated a putative interaction between smoking and
more » ... n smoking and CYP1A1 genotype and breast cancer risk using a case only study design. The genotype distribution of Thr461Asp in controls was close to that expected under Hardy-Weinberg equilibrium (HWE). We detected no significant differences in genotype frequencies between breast cancer cases and controls (P ⍧ 0.68). Compared with the Thr/Thr homozygotes there was no significant risk for either the Thr/Asp heterozygote [OR ⍧ 1.1 (95% CI 0.8-1.4)] or the Asp/Asp homozygote [OR ⍧ 0.4 (0.02-6.1)]. The genotype distribution of Ile462-Val in controls was also close to that expected under HWE with no significant differences between breast cancer cases and the controls (P ⍧ 0.44). No significant risk was found for either the Ile/Val heterozygote [OR ⍧ 0.8 (0.6-1.1)] or the Val/Val homozygote [OR ⍧ 2.7 (0.3-24)] compared with the Ile/Ile homozygotes. Furthermore, subgroup analyses revealed no effect of age or menopausal status on genotypic risks, and we found no evidence for an interaction between genotype and smoking habit or alcohol consumption and susceptibility to breast cancer. We combined our data for the Ile462Val polymorphism with those from four other published studies, but even with >5000 subjects, none of the genotype-associated risks achieved statistical significance, and there was no consistent pattern to the risks associated with increasing Val allele dosage [Ile/Val OR ⍧ 0.9 (0.7-1.1), Val/Val OR ⍧ 2.3 (0.4-12), and Val carrier OR ⍧ 1.0 (0.9-1.1)].
doi:10.1093/carcin/22.11.1797 pmid:11698341 fatcat:tch5pv54tfgxdichi7gmq4zkx4